TAO WU to Chemoradiotherapy
This is a "connection" page, showing publications TAO WU has written about Chemoradiotherapy.
Connection Strength
0.477
-
Risk-based, response-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. Am J Hematol. 2020 09; 95(9):1047-1056.
Score: 0.159
-
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leuk Lymphoma. 2019 11; 60(11):2669-2678.
Score: 0.147
-
Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. JAMA Netw Open. 2019 03 01; 2(3):e190194.
Score: 0.145
-
APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev Cell. 2014 May 27; 29(4):377-91.
Score: 0.026